Anti-inflammatory drug may lower type 2 diabetes risk
January 29th, 2008 - 3:00 pm ICT by admin
Washington, Jan 29 (ANI): A new study conducted by researchers at the Joslin Diabetes Center has revealed that an inexpensive anti-inflammatory drug salsalate, which is similar to aspirin, might prevent type 2 diabetes.
According to the researchers, the drug can fight the disease by lowering blood glucose and reducing inflammation.
They said that the study is promising enough to spur three more trials to see if salsalate can also treat diabetes by lowering blood glucose, slow the progression of coronary artery disease in those with metabolic syndrome, and perhaps prevent diabetes in those at high risk.
This is exciting because salsalate has a good safety profile after many years of use, is inexpensive to make and appears to have the potential to lower blood glucose. It may be useful in preventing diabetes,” said Allison B. Goldfine, M.D., lead researcher on the study, Head of Clinical Research at Joslin and Assistant Professor at Harvard Medical School.
She said that it has long been known that high doses of aspirin could reduce blood glucose levels, but the risk of stomach bleeding is too high to allow for this treatment to be used.
She also noted that it has also been known for several years that inflammatory markers and proteins are elevated in people with diabetes and that aspirin can reduce inflammation.
In animal studies, it has been shown that aspirin could be effective, but since it could not safely be used in humans at high doses, the researchers thought of designing a new drug.
They tried salsalate, a non-steroidal, anti-inflammatory medication that is similar to aspirin but does not cause bleeding in patients at risk for diabetes.
In the double-masked, placebo-controlled study of 20 obese young adults, the researchers found that salsalate substantially reduced blood glucose levels as well as inflammation, and, as a result, may eliminate their risk of developing type 2 diabetes.
Our study was the first to look at the metabolic changes that occur when you give salsalate to obese people who have not yet developed diabetes and were really encouraged by what we found, she said.
The study is published in the February issue of Diabetes Care. (ANI)
- Mediterranean diet a sound recipe for healthy living - Mar 08, 2011
- New aspirin curbs 11 kinds of cancer, shrinks tumours - Mar 09, 2012
- Turmeric 'the right spice' to fight colon cancer - Mar 03, 2011
- Study examines aspirin's ability to protect against colorectal cancer - Mar 10, 2011
- Taking antioxidants during pregnancy 'prevents obesity in kids' - Mar 15, 2011
- BP drug lowers weight in spite of high fat diet - Apr 13, 2012
- Human enzyme holds promise of weight loss - Nov 15, 2011
- Culprit for increased stroke injury with diabetes found - Jan 24, 2011
- Tart cherries may reduce inflammation, risk factors for heart disease - Apr 13, 2011
- Arthritis drug may help Type 2 diabetes patients - May 22, 2008
- Daily aspirin cuts bowel cancer death risk - Apr 26, 2012
- Taking aspirin for heart disease prevention is less costly, more effective - Feb 23, 2011
- How fish oils work against diabetes - Sep 03, 2010
- Protein that modulates metabolic dysfunction in obesity identified - Jun 18, 2010
- Variety in meals holds key to a long and healthy life - Oct 18, 2010
Tags: animal studies, anti inflammatory medication, aspirin, blood glucose levels, clinical research, coronary artery disease, diabetes risk, goldfine, harvard medical school, high risk, inflammation, inflammatory drug, inflammatory markers, joslin diabetes center, metabolic syndrome, preventing diabetes, safety profile, salsalate, type 2 diabetes, young adults